Featured Publications
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis
Farhat L, Behling E, Landeros-Weisenberger A, Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet Child & Adolescent Health 2022, 7: 112-126. PMID: 36528030, DOI: 10.1016/s2352-4642(22)00316-9.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychotic drugsMedication categoriesAntipsychotic drugsModerate certaintyIndividual medicationsTourette syndromePharmacological interventionsLow certaintyWHO International Clinical Trials Registry PlatformInternational Clinical Trials Registry PlatformSystematic reviewClinical Trials Registry PlatformChoice of medicationCochrane Central RegisterNetwork meta-analysis frameworkTrials Registry PlatformRandom-effects networkTerms of tolerabilityCertainty of evidenceClinical practice guidelinesComorbid attention deficit hyperactivity disorderStandardised mean differenceTreatment of childrenAttention deficit hyperactivity disorderWeb of ScienceThe effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis
Farhat LC, Flores JM, Behling E, Avila-Quintero VJ, Lombroso A, Cortese S, Polanczyk GV, Bloch MH. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molecular Psychiatry 2022, 27: 1562-1572. PMID: 35027679, DOI: 10.1038/s41380-021-01391-9.Peer-Reviewed Original ResearchConceptsFixed-dose trialAttention-deficit/hyperactivity disorderDose-limiting adverse eventsChildren/adolescentsAdverse eventsFlexible-dose trialTerms of efficacyClinical practiceHigh dosesFlexible dose designIntolerable adverse eventsHyperactivity disorderIncremental benefitLikelihood of discontinuationADHD symptomsLarge systematic reviewSchool-aged children/adolescentsFlexible titrationPotential long-term effectsSymptom controlTreatment discontinuationClinical outcomesStimulant dosesDaily dosesClinical guidelinesMeta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 884-893. PMID: 19625978, PMCID: PMC3943246, DOI: 10.1097/chi.0b013e3181b26e9f.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-AgonistsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityChildComorbidityContraindicationsDose-Response Relationship, DrugDouble-Blind MethodHumansMethylphenidatePropylaminesPsychotropic DrugsRandomized Controlled Trials as TopicTic DisordersTourette SyndromeConceptsAlpha-2 agonistsAttention-deficit/hyperactivity disorderTic symptomsComorbid ticsSupratherapeutic dosesTic disordersADHD symptomsTreatment of ADHDHyperactivity disorderPlacebo-controlled trialEfficacy of medicationsStandardized mean differenceEvidence-based treatmentsHalf of childrenComorbid tic disordersPrimary outcomeDifferent medicationsPsychostimulant medicationPubMed searchTic severityTourette syndromePackage insertsDrug AdministrationAtomoxetineSymptoms
2023
Editorial: Developmental considerations in addressing the earlier age of severe eating disorder onset
Kamody R, Bloch M. Editorial: Developmental considerations in addressing the earlier age of severe eating disorder onset. Journal Of Child Psychology And Psychiatry 2023, 64: 1101-1103. PMID: 37408467, DOI: 10.1111/jcpp.13852.Peer-Reviewed Original ResearchConceptsMental health concernsHealth concernYouth mental health careMental health careCOVID-19 pandemicImpact of ageYouth mental healthSevere presentationPediatric hospitalizationsDisorder onsetAge of childrenDisorder presentationsMental healthHealth careHospitalizationAgeEarly ageCareDisordersDevelopmental considerationsOnsetPresentationPandemicDeleterious impactThe genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis
Blanco-Vieira T, Radua J, Marcelino L, Bloch M, Mataix-Cols D, do Rosário M. The genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis. Translational Psychiatry 2023, 13: 230. PMID: 37380645, PMCID: PMC10307810, DOI: 10.1038/s41398-023-02433-2.Peer-Reviewed Original ResearchConceptsFirst-degree relativesSystematic reviewPopulation-based studyGenetic epidemiologyRelatives of childrenOutcomes of interestFirst systematic reviewObsessive-compulsive disorderRecurrence rateFamilial recurrence rateMedical recordsOpenGrey databasesControl groupControl probandsFamilial disorderAdolescent probandsStudy designEpidemiologyTwin study designOCD diagnosisIndependent researchersDizygotic twinsTwin pairsDisordersOCDCharacteristics of trichotillomania and excoriation disorder across the lifespan
Lin A, Farhat L, Flores J, Levine J, Fernandez T, Bloch M, Olfson E. Characteristics of trichotillomania and excoriation disorder across the lifespan. Psychiatry Research 2023, 322: 115120. PMID: 36842397, PMCID: PMC10023474, DOI: 10.1016/j.psychres.2023.115120.Peer-Reviewed Original ResearchConceptsExcoriation disorderClinical characteristicsSkin-picking severityAttention-deficit/hyperactivity disorderCo-occurring conditionsBody-focused repetitive behaviorsObsessive-compulsive disorderSeverity scoreCurrent symptomsSignificant positive correlationTrichotillomaniaHyperactivity disorderDisordersSelf-reported anxietyAge 4High rateSubtypesSelf-report measuresSeverityCross-sectional survey responsesRepetitive behaviorsAdulthoodPositive correlationThe Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial designSystematic review and meta-analysis: Season of birth and schizophrenia risk
Coury S, Lombroso A, Avila-Quintero V, Taylor J, Flores J, Szejko N, Bloch M. Systematic review and meta-analysis: Season of birth and schizophrenia risk. Schizophrenia Research 2023, 252: 244-252. PMID: 36682315, DOI: 10.1016/j.schres.2022.12.016.Peer-Reviewed Original ResearchConceptsRisk of schizophreniaSummer birthWinter birthSystematic reviewBirth monthVitamin D deficiencyStratified subgroup analysisSchizophrenia riskEtiological risk factorsMonth of birthD deficiencySeason of birthEtiologic causesSubgroup analysisVirus exposureRisk factorsSchizophreniaMonthsBirthSignificant differencesRiskAssociation
2022
Editorial: Schools on the frontline of suicide prevention
Kamody RC, Bloch MH. Editorial: Schools on the frontline of suicide prevention. Journal Of Child Psychology And Psychiatry 2022, 63: 833-835. PMID: 35861181, DOI: 10.1111/jcpp.13663.Peer-Reviewed Original ResearchConceptsMental health crisisYouth mental healthMental healthMental health careHealth crisisMental health fieldSuicide preventionBehavioral healthContinuum of servicesHealth careInnovative interventionsCOVID-19 pandemicIntervention approachesYouth behavioral healthCareHealthInequitable accessHealth fieldPandemicEditorial: We Can Do Better: Meta-analysis Demonstrates Inequities in Psychotherapy Efficacy for Black Children
Bloch MH, Finch K. Editorial: We Can Do Better: Meta-analysis Demonstrates Inequities in Psychotherapy Efficacy for Black Children. Journal Of The American Academy Of Child & Adolescent Psychiatry 2022, 61: 742-744. PMID: 35346785, DOI: 10.1016/j.jaac.2022.03.011.Peer-Reviewed Original Research
2021
Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder
Farhat LC, Vattimo EFQ, Ramakrishnan D, Levine JLS, Johnson JA, Artukoglu BB, Landeros-Weisenberger A, Asbahr FR, Cepeda SL, Comer JS, Fatori D, Franklin ME, Freeman JB, Geller DA, Grant PJ, Goodman WK, Heyman I, Ivarsson T, Lenhard F, Lewin AB, Li F, Merlo LJ, Mohsenabadi H, Peris TS, Piacentini J, Rosa-Alcázar AI, Rosa-Alcázar À, Rozenman M, Sapyta JJ, Serlachius E, Shabani MJ, Shavitt RG, Small BJ, Skarphedinsson G, Swedo SE, Thomsen PH, Turner C, Weidle B, Miguel EC, Storch EA, Mataix-Cols D, Bloch MH. Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2021, 61: 495-507. PMID: 34597773, DOI: 10.1016/j.jaac.2021.05.027.Peer-Reviewed Original ResearchConceptsPediatric obsessive-compulsive disorderObsessive-compulsive disorderOptimal cutoffYale-Brown ObsessiveCY-BOCSClinical trialsSystematic reviewClinical Global Impression-ImprovementRandom-effects meta-analysis modelDiscriminative abilityStandardized operational definitionsMeta-analysis modelChildren's Yale-Brown ObsessiveDiagnostic test accuracyTreatment responseRemissionSeverity ScaleMeta-AnalysisYouden indexCompulsive ScaleTrialsDisordersMeta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials
Nasir M, Li F, Courley S, Olten B, Bloch MH. Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials. Journal Of Child And Adolescent Psychopharmacology 2021, 31: 670-684. PMID: 34558984, DOI: 10.1089/cap.2021.0030.Peer-Reviewed Original ResearchConceptsPlacebo response ratesObsessive-compulsive disorderPlacebo responseDepression trialsResponse ratePlacebo improvementSymptom improvementAntidepressant trialsStratified subgroup analysisRandom-effects modelPediatric populationSubgroup analysisStudy visitNumber of subjectsPsychopharmacological trialsPubMed searchDifferent indicationsDiagnostic indicationsMean differenceAnxiety disordersTrialsDisordersPediatric anxietyPredictorsPossible correlatesDon’t Forget, Untreated Maternal Depression Poses Health Risks to the Child, Too
Behling E, Bloch MH. Don’t Forget, Untreated Maternal Depression Poses Health Risks to the Child, Too. Biological Psychiatry 2021, 90: 212-213. PMID: 34325804, DOI: 10.1016/j.biopsych.2021.06.010.Peer-Reviewed Original Research
2020
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study
Taylor JH, Appel S, Eli M, Alexander-Bloch A, Maayan L, Gur RE, Bloch MH. Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study. Journal Of Child And Adolescent Psychopharmacology 2020, 31: 46-52. PMID: 32633541, PMCID: PMC7891207, DOI: 10.1089/cap.2020.0030.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementClinical responseEarly Onset Schizophrenia Spectrum Disorders StudySymptom improvementWeek 8Early-onset schizophrenia spectrum disordersClinical response timeWeeks of treatmentProportional hazards regressionDisorders StudyTime courseSchizophrenia spectrum disordersClinical nonresponseMedication differencesClinical respondersTreatment initiationClinical nonrespondersMedian timeHazards regressionAntipsychotic treatmentEarly improvementSchizoaffective disorderClinical judgmentMore weeksYouth ages 8Little Doubt That CBT Works for Pediatric OCD
Storch EA, Peris TS, De Nadai A, Piacentini J, Bloch M, Cervin M, McGuire J, Farrell LJ, McCracken JT, McKay D, Riemann BC, Wagner AP, Franklin M, Schneider SC, Walkup JT, Williams L, Abramowitz JS, Stewart SE, Fitzgerald KD, Goodman WK. Little Doubt That CBT Works for Pediatric OCD. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 59: 785-787. PMID: 32618273, DOI: 10.1016/j.jaac.2020.01.026.Peer-Reviewed Original Research
2019
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 32-37. PMID: 31800306, PMCID: PMC7133418, DOI: 10.1089/cap.2019.0041.Peer-Reviewed Original ResearchConceptsCY-BOCS total scoreN-acetylcysteineYale-Brown ObsessiveTotal scorePlacebo groupNAC groupStudy populationBenefit of NACPlacebo-controlled clinical trialSymptom severityEffect of NACMild adverse eventsOCD symptom severityLarger study populationPediatric obsessive-compulsive disorderSmall pilot studyChildren's Yale-Brown ObsessiveStudy medicationAdverse eventsPrimary outcomeGlutamate dysfunctionObsessive-compulsive disorderWeek 12Future trialsNAC treatmentMeasuring Treatment Response in Pediatric Trichotillomania: A Meta-Analysis of Clinical Trials
Farhat LC, Olfson E, Levine JLS, Li F, Franklin ME, Lee HJ, Lewin AB, McGuire JF, Rahman O, Storch EA, Tolin DF, Zickgraf HF, Bloch MH. Measuring Treatment Response in Pediatric Trichotillomania: A Meta-Analysis of Clinical Trials. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 306-315. PMID: 31794677, PMCID: PMC7476376, DOI: 10.1089/cap.2019.0103.Peer-Reviewed Original ResearchConceptsClinical trialsTreatment responseOptimal cut pointCut pointsMassachusetts General Hospital Hair Pulling ScalePediatric trichotillomaniaClinical Global Impressions-Improvement scoreMeta-DiSc softwareClinical responsePediatric populationAge-related differencesSeverity ScaleImprovement scoresMeta-AnalysisYouden indexStandardized definitionsTTM severityOlder childrenTrichotillomaniaTrialsParent versionNational InstituteYoung childrenMGH-HPSDiscriminative abilityEfficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis.
Dobson ET, Bloch MH, Strawn JR. Efficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis. The Journal Of Clinical Psychiatry 2019, 80 PMID: 30753760, DOI: 10.4088/jcp.17r12064.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsTolerability of pharmacotherapyTreatment-emergent suicidalityMedication classesTreatment responsePediatric anxiety disordersAnxiety disordersReuptake inhibitorsTolerability of medicationsPlacebo-controlled trialSerotonin reuptake inhibitorsNetwork Meta-AnalysisRisk of biasWeb of ScienceCause discontinuationGeMTC packageSuicidality dataCochrane riskMultiple medicationsBias toolPediatric patientsMedication trialsAgonist treatmentCochrane Database
2018
Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD)
Banaschewski T, Belsham B, Bloch MH, Ferrin M, Johnson M, Kustow J, Robinson S, Zuddas A. Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD). Nutrition And Health 2018, 24: 279-284. PMID: 29921155, PMCID: PMC6291899, DOI: 10.1177/0260106018772170.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderPUFA supplementationDeficit hyperactivity disorderManagement of ADHDFurther high-quality researchHyperactivity disorderPossible side effectsSmall beneficial effectRobust evidence baseChild attention-deficit hyperactivity disorderFatty acidsFrontline treatmentHigh-quality researchCurrent evidenceSide effectsPsychosocial interventionsTreatment approachesPanel consensusPatientsBeneficial effectsEvidence baseSupplementationInternational expertsDisordersAdultsEditorial: Can omega‐3 fatty acids improve executive functioning? Will this reduce ADHD and depression?
Artukoglu BB, Bloch MH. Editorial: Can omega‐3 fatty acids improve executive functioning? Will this reduce ADHD and depression? Journal Of Child Psychology And Psychiatry 2018, 59: 615-617. PMID: 29808491, DOI: 10.1111/jcpp.12932.Peer-Reviewed Original Research